Key facts
- It has raised $82.8M; the latest was Later Stage VC ($48.5M) in Mar 2025.
- Notable investors include Mizuho Bank, Sumitomo Mitsui Trust Bank, Sumitomo Mitsui Banking Corporation, Jafco Investment (Asia Pacific), NSK Investment Partners — 22 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 22 names
- ·Watchlist + deal alerts for Chitose
- ·The full record, as it builds
Funding rounds
No funding rounds for Chitose are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Chitose
Developer of biotechnology-based technologies intended to build a sustainable global bioeconomy. The company offerswide range of technologies based on microorganisms, algae, and mammalian cells and utilizes these technologies for industrial use of the organism, enabling global markets to transition toward a bioeconomy that supports human life.
- Sector
- Healthcare
- HQ
- Singapore, Singapore
- Founded
- 2002
- Employees
- 100
- Website
- chitose-bio.com/
- Ownership
- Privately Held (backing)
Chitose doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Chitose shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Chitose in its N-PORT filings yet. We sweep new filings monthly.